Webinar on Successful IRT Partnerships

Given the specialist nature of IRT systems, it is now almost impossible for mid and small-sized pharma companies, and biotechs, to develop or maintain bespoke, internally-managed IRT systems. Most company staffing protocols simply don’t allow for the kind of infrastructure necessary to maintain such a specialist team, so we must inevitably look elsewhere for specialist IRT service providers.

BUT..

What happens when individual study teams are given the responsibility to select and manage their own chosen IRT vendor? How often have we seen one team encountering seemingly insurmountable difficulties, leading any teams following in their footsteps to automatically reject that IRT vendor, select another and subsequently experience very similar problems? How much better could the experience be if we were to invest proper time and effort with a single selected vendor, over time learning from our mistakes, improving our procedures and passing on knowledge to the study teams following behind us?

• What are the pitfalls when each team is allowed to select their own IRT vendor?
• What does a good IRT vendor partnership look like?
• What will we need to invest in order to develop a successful partnership?
• How do we choose a partner?
• Where could that partnership take us in the future?

Webinar : Reduce Build Time of IRT Systems.

As we move deeper into the 21st century, technologies available to clinical research teams are evolving at an ever-increasing rate. Whilst this evolution allows clinical trials to become increasingly smart and patient-centric it also runs the risk of making trials increasingly complicated with many more moving parts, third party vendors and data sources to integrate. With this in mind, how do we prevent these exciting new technologies that are designed to save us time and effort, from becoming the rate-limiting steps in the clinical trial set-up?

This webinar will examine both the stumbling blocks that have historically delayed the successful implementation of IRT systems and also new challenges that we increasingly face as the uptake in technological solutions intensifies. We will then explore some possible solutions; both quick-fixes and longer-term strategies that will take IRT development off the table as a rate-limiting step in the clinical trial set-up.

★ Understand the historical stumbling blocks that limit the speed of IRT set-up
★ Identify new challenges that emerge as technological solution uptake intensifies
★ Suggest some quick-fixes to see immediate improvements in development time
★ Explore potential longer-term strategies to reduce the build time of IRT

About Speaker:

Kate Chapman, the Director and Principal Consultant of Clinical Technology Consultants Ltd based in Winchester, UK, has 22 years of experience in the Clinical Development area of the Pharmaceutical and Biotechnology sector, having worked at multiple Pharma companies including Novartis, Roche, Sanofi, BMS, Pharmacia and Shire, and has a deep expertise in IRT. Kate has extensive experience of IRT systems and continuously reviews many of the systems that are currently available and those that are under development. In her capacity as a consultant, she works with both large Pharma and small Biotech companies helping them to get the most out their IRT systems and their partnerships with a wide variety of IRT vendors.